Soligenix (SNGX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Aug, 2026Executive summary
Annual meeting scheduled for September 17, 2026, with virtual participation available.
Shareholders are invited to vote on key proposals, including board elections, amendments to the certificate of incorporation, and executive compensation.
Voting matters and shareholder proposals
Election of five directors to serve until the next annual meeting or until successors are elected.
Proposal to approve a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the board's discretion, effective for up to one year.
Proposal to increase authorized common stock from 75,000,000 to 125,000,000 shares.
Advisory vote on executive compensation and on the frequency of such advisory votes.
Ratification of Cherry Bekaert LLP as independent auditor for the year ending December 31, 2026.
Approval to adjourn the meeting if necessary to solicit more proxies.
Board of directors and corporate governance
Nominees for director positions include Christopher J. Schaber, Gregg A. Lapointe, Diane L. Parks, Robert J. Rubin, and Jerome B. Zeldis.
Latest events from Soligenix
- Proxy seeks approval for reverse split, share increase, and highlights governance and ESG focus.SNGX
Proxy filing3 Aug 2026 - Reverse split and share increase proposed to maintain Nasdaq listing and enable future growth.SNGX
Proxy filing23 Jul 2026 - Proxy seeks approval for reverse split, share increase, director elections, and executive pay.SNGX
Proxy filing21 Jul 2026 - Net loss narrowed, FLASH2 trial halted, focus shifts to pipeline amid funding risks.SNGX
Q1 202611 May 2026 - Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation8 Apr 2026 - Net loss rose to $11.1M in 2025, with liquidity concerns and new capital needed for continued operations.SNGX
Q4 202531 Mar 2026 - Late-stage rare disease therapies and vaccines show strong clinical and commercial promise.SNGX
Corporate presentation26 Mar 2026 - Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data.SNGX
Corporate presentation20 Mar 2026 - Proxy seeks approval of director slate, new equity plan, executive pay, and auditor ratification.SNGX
Proxy Filing2 Dec 2025